Table 4.
Case reports and case series describing candidemia associated with COVID-19.
| Characteristics | No. (%) |
|---|---|
| Candidemia cases | 41 |
| Sex | Male: 32 (78) |
| Median age (IQR) | 64 (54–72) |
| Main underlying diseases | Diabetes mellitus: 27 (65.9) Arterial hypertension: 24 (58.5) Cardiovascular disease: 9 (21.9) Obesity: 9 (21.9) Chronic pulmonary disease: 4 (9.8) |
| COVID-19 treatments | Steroids: 27 (65.9) Tocilizumab: 8 (19.7) Baricitinib: 7 (17.1) |
| Median number of days from ICU admission or TI to candidemia (IQR) |
13.5 (7.5–29.5) |
| No. of patients with central venous catheters | 35 (85.4) |
| No. of patients on total parenteral nutrition | 5 (12.8) |
| No. of patients on antibiotic therapy | 34 (82.9) |
| No. of patients undergoing mechanical ventilation | 36 (87.8) |
| Candida species |
C. albicans: 18 (40.9) C. auris: 11 (26.8) C. glabrata: 6 (14.6) C. tropicalis: 4 (9.8) Other: 5 (12.2) Total: 44 |
| No. of patients with a secondary focus | Retinitis: 1 Endocarditis: 1 Endophathalmitis: 1 Osteomyelitis: 1 |
| No. patients receiving anti-fungal treatment Anti-fungal agents |
36 (87.8) Anidulafungin: 16 (44.4) Caspofungin: 13 (36.1) Fluconazole: 12 (33.3) Other azoles: 5 (13.9) AMB: 4 (11.1) Other: 3 (8.3) |
| Number of deaths | 23 (56.1) |
Data are absolute numbers (percentages) unless otherwise specified. Abbreviations: ICU, intensive care unit; IQR, interquartile range; TI, tracheal intubation; AMB, amphotericin B.